Published Online:9 May 2008https://doi.org/10.2217/14622416.9.5.527
Abstract
Background: Clobazam-induced adverse reactions have been reported in cases with CYP2C19 defective allele(s). However, the relevance of the CYP2C19 genotypes to clobazam therapy remains to be clarified. Methods: The association between CYP2C19 genotypes and the antiepileptic and adverse effects of clobazam was retrospectively investigated in 110 Japanese subjects, in relation to clobazam and N-desmethylclobazam (N-clobazam) concentrations. Results: There were 41 (37.3%) homozygous extensive metabolizers (EMs), 44 (40.0%) heterozygous EMs, and 25 (22.7%) poor metabolizers (PMs). The response rate was significantly greater in PMs and heterozygous EMs than homozygous EMs with a gene–dose effect (65.2, 47.6 and 33.3%, respectively), and the adjusted odds ratio (95% CI) of PM versus homozygous EMs was 9.88 (2.47–39.56; p = 0.001). However, the genotypes did not affect the development of tolerance or adverse reactions, although the incidence of some adverse symptoms was insignificantly higher in PMs. The N-clobazam concentration (µg/ml) increased with the number of CYP2C19-defective alleles (0.92 ± 0.61, 2.14 ± 1.69 and 7.70 ± 6.04, respectively; p < 0.001), while the clobazam concentration was 1.5-fold greater in those with at least one variant. Conclusion:CYP2C19 genotype had an impact on the efficacy of clobazam, thus indicating that N-clobazam plays an important role in long-term clobazam therapy.
Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Bibliography
- 1 Dicchter MA, Brodie MJ: New antiepileptic drugs. N. Engl. J. Med.334,1583–1590 (1996).Crossref, Medline, Google Scholar
- 2 Shorvon SD: Benzodiazepines: clobazam. In: Antiepileptic Drugs (4th Edition). Levy RH, Mattoson RH, Meldrum BS (Eds). Raven Press Ltd, NY, USA, 763–777 (1995).•• Summarizes the antiepileptic effects of clobazam.Google Scholar
- 3 Ng YT, Collins SD: Clobazam. Neurotherapeutics4,138–144 (2007).Crossref, Medline, CAS, Google Scholar
- 4 Shorvon SD: The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia39(Suppl. 1),S15–S23 (1998).Crossref, Medline, CAS, Google Scholar
- 5 Canadian Clobazam Cooperative Group: Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia32,407–416 (1991).• Provides a large-scale, multicenter study of clobazam.Crossref, Medline, Google Scholar
- 6 Kilpatrick C, Bury R, Fullinfaw R, Moulds R: Clobazam in the treatment of epilepsy. Clin. Exp. Neurol.23,139–144 (1987).Medline, CAS, Google Scholar
- 7 Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G: In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab. Dispos.32,1279–1286 (2004).•• Demonstrates that clobazam and N-desmethylclobazam (N-clobazam) are metabolized by CYP2C19.Crossref, Medline, CAS, Google Scholar
- 8 Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev.58,521–590 (2006).Crossref, Medline, CAS, Google Scholar
- 9 de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem.269,15419–15422 (1994).Crossref, Medline, CAS, Google Scholar
- 10 de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol.46,594–598 (1994).Medline, CAS, Google Scholar
- 11 Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A: Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther. Drug Monit.24,737–741 (2002).•• First suggested that CYP2C19 polymorphisms may influence clobazam therapy.Crossref, Medline, CAS, Google Scholar
- 12 Parmeggiani A, Posar A, Sangiorgi S, Giovanardi-Rossi P: Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain Dev.26,63–66 (2004).Crossref, Medline, Google Scholar
- 13 Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T: A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev.26,530–534 (2004).•• Provides evidence that CYP2C19 polymorphism affects clobazam pharmacokinetics.Crossref, Medline, Google Scholar
- 14 WHO: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992. WHO, Geneva, Switzerland.Google Scholar
- 15 Seo T, Ishitsu T, Ueda N et al.: ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics7,551–561 (2006).Link, CAS, Google Scholar
- 16 Brodie MJ, Dichter MA: Antiepileptic drugs. N. Engl. J. Med.334,168–175 (1996).Crossref, Medline, CAS, Google Scholar
- 17 Kwan P, Brodie MJ: Early identification of refractory epilepsy. N. Engl. J. Med.342,314–319 (2000).Crossref, Medline, CAS, Google Scholar
- 18 Ferraro TN, Dlugos DJ, Buono RJ: Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics7,89–103 (2006).Link, CAS, Google Scholar
- 19 Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P: Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia48,497–504 (2007).Crossref, Medline, CAS, Google Scholar
- 20 Glauser TA, Ayala R, RD Elterman et al.: Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology66,1654–1660 (2006).Crossref, Medline, CAS, Google Scholar
- 21 Löscher W, Schmidt D: Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia47,1253–1284 (2006).Crossref, Medline, Google Scholar
- 22 Naranjo CA, Busto U, Sellers EM et al.: A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther.30,239–245 (1981).Crossref, Medline, CAS, Google Scholar
- 23 Minami K, Nemoto K, Narabe Y: A simple HPLC method for measurement of drugs. Jpn J. Clin. Chem.33(Suppl. 3),185 (2004).Google Scholar
- 24 Richards B, Skoletsky J, Shuber AP et al.: Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum. Mol. Genet.2,159–163 (1993).Crossref, Medline, CAS, Google Scholar
- 25 Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4´-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther.60,661–666 (1996).Crossref, Medline, CAS, Google Scholar
- 26 Contin M, Riva R, Albani F, Baruzzi AA: Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther. Drug Monit.21,604–608 (1999).Crossref, Medline, CAS, Google Scholar
- 27 Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K: Use of clobazam for the treatment of refractory complex partial seizures. Seizure12,282–286 (2003).Crossref, Medline, Google Scholar
- 28 Montenegro MA, Cendes F, Noronha AL et al.: Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia42,539–542 (2001).Crossref, Medline, CAS, Google Scholar
- 29 Fielding S, Hoffmann I: Pharmacology of anti-anxiety drugs with special reference to clobazam. Br. J. Clin. Pharmacol.7(Suppl. 1),S7–S15 (1979).Crossref, CAS, Google Scholar
- 30 Haigh JR, Pullar T, Gent JP, Dailley C, Feely M: N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy? Br. J. Clin. Pharmacol.23,213–218 (1987).• Suggests that N-clobazam may be preferable to clobazam for clinical efficacy.Crossref, Medline, CAS, Google Scholar
- 31 Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M: Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia37,728–735 (1996).Crossref, Medline, CAS, Google Scholar
- 32 Giraud C, Treluyer JM, Rey E et al.: In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab. Dispos.34,608–611 (2006).Crossref, Medline, CAS, Google Scholar
- 33 Chiron C, Marchand MC, Tran A et al.: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet356,1638–1642 (2000).Crossref, Medline, CAS, Google Scholar
- 34 Remy C: Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia35(Suppl. 5),S88–S91 (1994).Crossref, Medline, Google Scholar
- 35 Sugai K: Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia45(Suppl. 8),20–25 (2004).Crossref, Medline, CAS, Google Scholar
- 36 Depondt C, Shorvon SD: Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. Pharmacogenomics7,731–745 (2006).Link, CAS, Google Scholar
